Specific Systems of Treatment
injured, but in the body were destroyed. There- fore an indirect mechanism was involved. Fur- ther examination revealed that the cancer cells were not directly poisoned.
Gold also found that hydrazine sulfate could be used to increase the effectiveness of regular cell- poisoning drugs (chemotherapy) in animals. Per- haps best of all, if only small amounts were used, the chemical compound did its work without poisoning the normal cells. It is in no way a killer cell of any kind—including malignant ones. It only works by blocking a certain liver enzyme, needed to provide energy to the metabolism of the tumor.
In 1973, Gold published his first report on his findings, and then gave a talk about it at the New York Academy of Sciences. Afterward, a phy- sician came up and asked for further data on how to dispense it, since he had a woman cancer pa- tient who, within three or four days, would be dead.
Within a few weeks, the woman was dramati- cally improved, and on her feet again. A number of other patients also experienced improvement. By August 1973, 20 or 30 patients were taking it in various parts of the country. By October, there were over a thousand.
Gold began to experience difficulties in his re- quests for further funds from NCI for research. But Dr. Dean Burk was still at NCI. He it was who had himself amplified somewhat on the work of Warburg. Gold’s findings vindicated both Warburg and Burk’s research into cancer cell metabolism.
Burk was enthusiastic, and said so. He re- leased this memorandum to the scientific commu- nity in mid-1973:
“Since April 1, 1973, upwards of 30 cachetic or ‘terminal’ cancer patients have been treated with gelatin capsules containing 60 mg of hy- drazine sulfate three to four times a day (at in- tervals of about 6 hours). Usually within 24-48 hours there is a marked return of appetite fol- lowed by continued increase in weight, remark- ably restored physical activity, and eventually decrease in tumor size, decrease in pain, and related decrease in symptomatology.”—Dean Burk, Memorandum, Department of Health, Education, and Welfare, National Institutes of Health, August 10, 1973. About six months later, Burk wrote: “[Hydrazine sulfate is] the most remarkable anti-cancer agent I have come across in my forty-five years of experience in cancer . . It would make little difference with hydrazine sulfate if the FDA wanted to balk, because this material is so cheap—and it is cheap because it is made by the trainload for industrial pur- poses.”—Dean Burk, “New Approaches to Can-
cer Therapy,” New England Natural Food As- sociation Bulletin, Spring 1974.
In a paper on the subject, presented before top officials at Sloan-Kettering Institute in New York, Burk said this: “Let me tell you this perfectly true story . . I could give you many. A woman with Hodgkin’s disease who had been flat on her back for seven weeks, who had no appetite and who had lost all her weight—a ‘paper-thin’ patient—took hy- drazine sulfate. One week later she was shop- ping in the grocery store with her own bag; five day later she was spending most of the day in her garden. I don’t give that as any miraculous story—it is simply the plain truth.”—Ibid.
Hydrazine sulfate, because it was a chemical, was immediately put into clinical trials by the che- motherapy department at Sloan-Kettering. Since it had already been tried on humans, and since news of it was so widespread among physicians and somewhat among the general public, an- nouncement was made in September that a joint SKI-Syracuse Cancer Research Institute study would begin.
But, following that announcement, officials at SKI immediately drew back, and their participa- tion was only deleterious. Patients who died be- fore receiving even one dose were listed as “fail- ures.” Instead of receiving the optimal dosage (which was 60 milligrams of hydrazine sulfate for the first three days, 60 milligrams twice a day for the next three days, and 60 milligrams three times a day thereafter), SKI had them start with 1 milligram a day for the first day, 2 for the second, etc., until they reached 20 or 30 milligrams a day.
When Gold appealed to them to abide by the original dosage agreement, SKI ordered a single massive dose of 120-190 mg. to be given. This high dosage was toxic in the extreme, and elimi- nated all earlier improvements. According to Gold, the SKI chemotherapist told a relative of one of the patients that he had no ”enthusiasm or in- terest in” hydrazine sulfate and that it was “worth- less” in the treatment of cancer (ibid.).
In the summer of 1974, Gold told a packed audience at a National Health Federation conven- tion about the benefits of hydrazine sulfate. This caused the news about the compound to travel even farther.
In response, the FDA issued a directive block- ing access to the compound by physicians and making it illegal for chemical companies to sell hydrazine sulfate directly to the public.
That announcement was immediately preceded by an official statement issued by the public af-